Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports. // Biomedicine & Pharmacotherapy. – URL: https://www.sciencedirect.com/science/article/pii/S0753332226010127?dgcid=rss_sd_all
Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports. Biomedicine & Pharmacotherapy. https://www.sciencedirect.com/science/article/pii/S0753332226010127?dgcid=rss_sd_all
“Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports.” Biomedicine & Pharmacotherapy.
@article{article38165,
title = {Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports},
journal = {Biomedicine \& Pharmacotherapy},
url = {https://www.sciencedirect.com/science/article/pii/S0753332226010127?dgcid=rss_sd_all}
}